A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients.
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2014
At a glance
- Drugs Pramipexole (Primary) ; Ropinirole
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 14 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 09 Dec 2008 Status changed from recruiting to active, no longer recruiting, as reported on ClinicalTrials.gov.
- 11 Dec 2005 New trial record.